Posters –
Immunology and Oncology
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Cytokine Pathway Inhibitor
Rémi PICARD
SATT Sud Est
Researchers showed that 3 cytokines (CXCL1, 7 and 8) and CXCL receptors (CXCR1 and
CXCR2) are overexpressed in tumorous kidney cells and are markers of bad prognosis.
Technology
They produced 2 tri-specific monoclonal antibodies able to inhibit simultaneously the
CXCL1, 7 and 8. These antibodies show high affinity for the 3 CXCL and a significant
inhibition of the tumor growth in mouse xenograft models of renal cell carcinoma.
3 competitive advantages:
- Novel multi-target monoclonal antibodies active in emerging pathway: CXCL1, 7, 8
- Anti-angiogenic/inflammatory and proliferative–metastatic MOA
- Multiple targets (3) designed to prevent «tumor escape»: the most over-expressed CXCL
are simultaneously inhibited
Customers / Target market
Second line immunotherapy for renal cell carcinoma
Companion test for anti-CXCL therapy
Other considered application: treatment of breast cancer HER2- significant recent
literature underlying the key function of the CXCL pathway in the regulation of cancer
stem cells particularly in HER2 Breast Cancer
Industry and competitors
Same inhibition profile of tumor growth with the monoclonal antibodies than the gold
standard Sutent
Financing need / Commercial
opportunity
IP – Patent situation
We are currently looking for an industrial partner interested for licensing-in the
technology and/or R&D collaboration (possible co-funding)
Patent: entry into national phases
Future steps / Milestones
We are looking for a company interested to further develop this concept. We also plan to
validate the CXCL antibodies for breast cancer treatment
Further reading
The ELR+CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new
target for the treatment of renal cell carcinoma, Sandy Giuliano, Mélanie Guyot, Renaud
Grépin & Gilles Pagès, Apr 2014, OncoImmunology
Contact person
Patrick Jourdan, Business Development Manager, SATT Sud Est,
patrick.jourdan@sattse.com